Research and Developments

Page 1 of 2012345...1020...Last »

December 21, 2017

Apellis Entering Phase 3 Trials for Dry Macular Degeneration

Posted in: Latest News, Research and Developments

Apellis Pharmaceuticals has announced that it has finalized the trial design for its planned Phase 3 program evaluating APL-2 for the treatment of patients with geographic atrophy (GA), aka dry macular degeneration. The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical studies to assess the efficacy
read more »

December 20, 2017

FDA Approves First Gene Therapy for Inherited Retinal Dystrophy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

The U.S. Food and Drug Administration (FDA) has approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy developed by Spark Therapeutics, to treat an inherited form of vision loss that can result in blindness.  The most prevalent inherited retinal dystrophies are retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Stargardt disease (SD), all of which have
read more »

December 6, 2017

Iluvian Continues to Show Good Results in DME Trials

Posted in: Latest News, Research and Developments

We reported here in 2015 that Iluvian, a unique drug implant devised by Alimera Sciences, had entered trials for treatment of diabetic macular edema (DME). The drug is a corticosteroid that has demonstrated effectiveness in the treatment of DME without the need for monthly injections. Jay Prensky, MD (investigator for Alimera Sciences) reported to the
read more »

November 27, 2017

Regeneron Study of Nesvacumab Discontinued

Posted in: Latest News, Research and Developments

It was recently reported here that nesvacumab (REGN910) was being tested in combination with Eylea (Regeneron) as a potential treatment for wet AMD. Regeneron, however, reported on November 27 that the results “did not provide sufficient differentiation to warrant Phase 3 development.” The Phase 2 trials have, therefore, been discontinued, and research data will be
read more »

November 20, 2017

Two New Antiangiogenic Drugs Under Study for Wet AMD and DME

Posted in: Latest News, Research and Developments

Since 2005, anti-VEGF drug injections have proved effective for treatment of neovascularization* secondary to age-related macular degeneration (AMD) and diabetic macular edema (DME). Several newer anti-VEGF therapies are also under study, including PAN-90806, OPT-302, ICON-1, RGX-314, and RTH258. All of these are described and sourced on this site. Recently, scientists have researched a possible counterpart
read more »

November 18, 2017

Incidence of AMD Dramatically Declining

Posted in: Latest News, Research and Developments

A recent observational study at the University of Wisconsin-Madison has found that the risk of developing age-related macular degeneration (AMD) has been dramatically lessening over three generations. After looking at follow-up data on 4,819 participants and their offspring in the Beaver Dam studies (1987-2013), Karen J. Cruickshanks, Ph.D. et al found that the incidence of
read more »

November 16, 2017

Two Trials Take First Step Toward Stem Cell Treatment for AMD

Posted in: Latest News, Research and Developments

Results from two new clinical trials have added support for the use of human embryonic stem cells as treatment for the dry form of macular degeneration. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients’
read more »

November 11, 2017

Brolucizimab May Be the Next Treatment Option for Wet AMD

Posted in: Latest News, Research and Developments

Swiss drugmaker Novartis has announced that their new anti-VEGF drug, brolucizumab (RTH258), is meeting expectations as a potentially more effective and longer lasting treatment for wet macular degeneration than at least one of the current options. Positive results from two Phase III studies of brolucizumab versus aflibercept (Eylea) were presented at the American Academy of
read more »

October 24, 2017

New Sub-retinal Implant For Dry AMD Entering Trials

Posted in: Latest News, Research and Developments

(Updated January 2018) Alongside research to find ways of restoring vision through stem cell therapy and gene therapy, attempts are being made to restore vision electronically by means of bionic implants. In past reports, we have described the ARGUS-2, which has shown success in providing a basic pixelated sense of sight to the totally blind.
read more »

September 9, 2017

Lampalizumab for Dry AMD Unable to Meet Expectations in Phase III Trial

Posted in: Latest News, Research and Developments

Genentech has announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab. Lampalizumab, as reported here in July 2016, is an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). It was designed to inhibit Complement Factor D,
read more »

Page 1 of 2012345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann